<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>生物科技和医疗保健类股票在周三的盘后交易中表现突出，几家小型公司的股价因企业更新和投资者的积极情绪而大幅上涨。</p>
<p>Plus Therapeutics, Inc. (PSTV) 在宣布其承销公开发行定价后，股价上涨 8.40%，收于 0.31 美元。该公司正在发行 39,473,684 个单位，每个单位由一股普通股和一个认股权证组成，发行价为每单位 0.38 美元。预计在扣除费用之前，毛收益总额约为 1500 万美元。这笔融资为 Plus Therapeutics 提供了新资本，以推进其针对中枢神经系统癌症的精准诊断和放射药物项目。</p>
<p>Connect Biopharma Holdings Limited (CNTB) 在盘后交易中上涨 5.96%，至 2.31 美元。尽管周三没有发布新消息，但该公司最近强调了其主要候选药物 rademikibart 的新机制数据，并概述了 2026 年的战略优先事项。</p>
<p>ABVC BioPharma, Inc. (ABVC) 上涨 3.37%，收于 2.15 美元。此次上涨没有任何新的企业更新，表明投资者的兴趣可能受到更广泛行业动向的推动。</p>
<p>Modular Medical, Inc. (MODD) 在盘后交易中上涨 5.23%，至 0.49 美元。该公司周三没有发布任何消息，但其股票重新吸引了买盘兴趣。</p>
<p>Traws Pharma, Inc. (TRAW) 上涨 2.82%，至 1.82 美元。本周早些时候，该临床阶段生物制药公司宣布向 FDA 提交了 tivoxavir marboxil (TXM) 的美国 IND 申请，这是一种潜在的最佳口服流感治疗药物。该更新继续支持投资者对公司管道的乐观情绪。</p>
<p>Tiziana Life Sciences Ltd (TLSA) 在盘后交易中上涨 2.72%，至 1.51 美元。周三没有报告新的进展。</p>
<p>Elutia Inc. (ELUT) 上涨 6.64%，至 0.90 美元。该公司在 1 月 12 日提供了企业更新，并概述了其下一代抗生素释放生物基质项目 NXT-41x 的即将里程碑。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

PSTV

康乃德生物制药

ELUT

<p>生物科技股票在盘后交易中出现显著波动，Plus Therapeutics, Inc. (PSTV) 领涨，涨幅达到 8.40%，至 0.31 美元，此前该公司宣布以每单位 0.38 美元的价格进行公开募股，预计筹集 1500 万美元。其他 notable 的涨幅股票包括 Connect Biopharma (CNTB) 上涨 5.96%，ABVC BioPharma (ABVC) 上涨 3.37%，以及 Modular Medical (MODD) 上涨 5.23%。Traws Pharma (TRAW) 在提交 IND 申请后上涨 2.82%，而 Elutia Inc. (ELUT) 在概述其新生物基质项目的里程碑后上涨 6.64%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting strong gains on the back of corporate updates and investor momentum.</p>
<div class="lb-trans"><p>生物科技和医疗保健类股票在周三的盘后交易中表现突出，几家小型公司的股价因企业更新和投资者的积极情绪而大幅上涨。</p>
</div><p>Plus Therapeutics, Inc. (PSTV) surged 8.40% to close at $0.31 after announcing the pricing of its underwritten public offering. The company is issuing 39,473,684 units, each consisting of one share of common stock and one warrant, at $0.38 per unit. Gross proceeds are expected to total approximately $15 million before expenses. The financing provides Plus Therapeutics with fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.</p>
<div class="lb-trans"><p>Plus Therapeutics, Inc. (PSTV) 在宣布其承销公开发行定价后，股价上涨 8.40%，收于 0.31 美元。该公司正在发行 39,473,684 个单位，每个单位由一股普通股和一个认股权证组成，发行价为每单位 0.38 美元。预计在扣除费用之前，毛收益总额约为 1500 万美元。这笔融资为 Plus Therapeutics 提供了新资本，以推进其针对中枢神经系统癌症的精准诊断和放射药物项目。</p>
</div><p>Connect Biopharma Holdings Limited (CNTB) gained 5.96% to $2.31 in after-hours trading. While no fresh news was released on Wednesday, the company recently highlighted new mechanism of action data for its lead candidate, rademikibart, and outlined strategic priorities for 2026.</p>
<div class="lb-trans"><p>Connect Biopharma Holdings Limited (CNTB) 在盘后交易中上涨 5.96%，至 2.31 美元。尽管周三没有发布新消息，但该公司最近强调了其主要候选药物 rademikibart 的新机制数据，并概述了 2026 年的战略优先事项。</p>
</div><p>ABVC BioPharma, Inc. (ABVC) added 3.37% to finish at $2.15. The move came without any new corporate updates, suggesting investor interest may be driven by broader sector momentum.</p>
<div class="lb-trans"><p>ABVC BioPharma, Inc. (ABVC) 上涨 3.37%，收于 2.15 美元。此次上涨没有任何新的企业更新，表明投资者的兴趣可能受到更广泛行业动向的推动。</p>
</div><p>Modular Medical, Inc. (MODD) advanced 5.23% to $0.49 after hours. The company did not issue any news on Wednesday, but shares saw renewed buying interest.</p>
<div class="lb-trans"><p>Modular Medical, Inc. (MODD) 在盘后交易中上涨 5.23%，至 0.49 美元。该公司周三没有发布任何消息，但其股票重新吸引了买盘兴趣。</p>
</div><p>Traws Pharma, Inc. (TRAW) rose 2.82% to $1.82. Earlier this week, the clinical-stage biopharma announced the filing of a U.S. IND application with the FDA for tivoxavir marboxil (TXM), a potential best-in-class oral therapy for influenza. The update continues to support investor optimism around the company's pipeline.</p>
<div class="lb-trans"><p>Traws Pharma, Inc. (TRAW) 上涨 2.82%，至 1.82 美元。本周早些时候，该临床阶段生物制药公司宣布向 FDA 提交了 tivoxavir marboxil (TXM) 的美国 IND 申请，这是一种潜在的最佳口服流感治疗药物。该更新继续支持投资者对公司管道的乐观情绪。</p>
</div><p>Tiziana Life Sciences Ltd (TLSA) posted a 2.72% gain to $1.51 in after-hours trading. No new developments were reported on Wednesday.</p>
<div class="lb-trans"><p>Tiziana Life Sciences Ltd (TLSA) 在盘后交易中上涨 2.72%，至 1.51 美元。周三没有报告新的进展。</p>
</div><p>Elutia Inc. (ELUT) climbed 6.64% to $0.90. On January 12, the company provided a corporate update and outlined upcoming milestones for NXT-41x, its next-generation antibiotic-eluting biomatrix program designed for use in plastic and reconstructive surgery.</p>
<div class="lb-trans"><p>Elutia Inc. (ELUT) 上涨 6.64%，至 0.90 美元。该公司在 1 月 12 日提供了企业更新，并概述了其下一代抗生素释放生物基质项目 NXT-41x 的即将里程碑。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Plus Therapeutics 在盘后生物技术股集会上带动上涨；康乃德生物制药和 Elutia 也有所上涨